Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025571 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025571 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute.
The verdict
NCT00025571, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have non-small cell lung cancer.
Interventions
- DRUG HPPH
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025571
The ClinicalTrials.gov registry entry for NCT00025571 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HPPH is the first listed.
NCT00025571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025571 about?
NCT00025571 is a clinical study titled "Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectivene...
What is the current status of trial NCT00025571?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00025571?
The interventions under investigation include: HPPH (DRUG).
Who is sponsoring clinical trial NCT00025571?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.